“Unlocking Hope: Vigil Neurosciences’ Alzheimer’s Treatment Shows Promising Safety Results, Set to Begin Mid-Stage Trial in Q3”
The Latest Breakthrough in Alzheimer’s Disease Treatment Exciting News from Vigil Neuroscience Inc. On Thursday, Vigil Neuroscience Inc. VIGL released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease. Alzheimer’s disease is a devastating condition that affects millions of individuals worldwide. It is a progressive neurodegenerative disorder that…